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EBV-ASSOCIATED LEIOMYOMAS FOLLOWING HAPLOIDENTICAL
TRANSPLANTATION FOR X-LINKED SEVERE COMBINED IMMUNODEFI-
CIENCY DISEASE
Robertson, K.A.1, Alturi, S.1, Neville, K.1, Davis, M.1,
Marshalleck, F.E.1, Buckley, R.H.2, Nelson, R.P.1 1Indiana University
School of Medicine, Indianapolis, IN; 2Duke University Medical Center,
Durham, NC.
In the setting of transplantation, Epstein-Barr virus (EBV) is
most commmonly associated with posttransplantation lymphopro-
liferative disease; however, there are reports of EBV associated
leiomyomas for which the virus has some tropism. We wish to
report the ﬁrst case of EBV-associated leimyomas following hap-
loidentical BMT for X-linked severe combined immune deﬁciency
(SCID). Twin A is an 8-year-old boy who along with his syngeneic
twin (B) received a paternal T-cell–depleted haploidentical BMT
for X-linked SCID at 10 days of life. Twin B experienced rapid
donor T-cell engraftment with restored cellular function. Twin A’s
course was complicated by incomplete donor T-cell engraftment,
multiple infections, and GVHD. Twin A received a booster twin-
to-twin infusion of unfractionated marrow, resulting in an im-
proved lymphocyte counts, mitogen stimulation response, and
clinical improvement without worsening of GVHD. The patient
(twin A) did well over the next 6 years until he developed fatigue,
weight loss, and exercise-induced shortness of breath. CT scans
revealed bilateral renal masses (4 on the right and 2 on the left)
with a left pleural-based lung mass. Percutaneous renal biopsy
demonstrated leiomyoma with a spindle cell histology. The tumor
cells were positive for Ki-67 and actin, but negative for S-100
protein and HMB45. EBV PCR on parafﬁn-embedded tissue was
positive. EBV serologies were unhelpful on both twins as they
remain on intravenous immunoglobulin supplementation, but
EBV PCR was negative from the peripheral blood of twin B and
positive for twin A at 2400 copies per mL. T-cell chimerism studies
showed a decrease in donor T-cell engraftment in twin A. Twin A
continued to show weight loss with persistant symptoms and was
subsequently given an infusion of 106 peripheral blood lympho-
cytes per kg body weight from twin B to supplement his graft. Over
the next 4 months, the patient (twin A) has shown an increase in
T-cell numbers, improvement in clinical symptoms, weight gain,
and stabilization of his leiomyomas.
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RESULTS OF THE CORD BLOOD TRANSPLANTATION STUDY (COBLT):
CLINICAL OUTCOMES OF UNRELATED DONOR UMBILICAL CORD
BLOOD TRANSPLANTATION IN PEDIATRIC PATIENTS WITH INBORN
ERRORS OF METABOLISM
Kurtzberg, J.1, Carter, S.L.2, Sahdev, I.3, Wall, D.4, Pietryga, D.5,
Wagner, J.E.6, Kernan, N.A.7 1Duke University Medical Center,
Durham, NC; 2/ The EMMES Corporation, Rockville, MD; 3Schneider
Children’s Hospital, New Hyde Park, NY; 4Texas Transplantation
Institute, San Antonio, TX; 5DeVos Children’s Hospital, Grand Rapids,
MI; 6University of Minnesota, Minneapolis, MN; 7Memorial Sloan-
Kettering Cancer Center, New York, NY.
The Cord Blood Transplantation Study (COBLT), sponsored by
the National Heart, Lung, and Blood Institute, evaluated the
outcomes of unrelated donor umbilical cord blood transplantation
(UCBT) in 32 patients (56% males; 75% Caucasian) with inborn
errors of metabolism. A common protocol was used for the pre-
parative regimen (busulfan, cyclophosphamide, ATG) and GvHD
prophylaxis (cyclosporine and steroids). Patients with MPS I Hurl-
er’s syndrome (n  13; 12 reported NEJM 2004:350:1960–9),
Hurler-Sheie syndrome (n  2), Sanﬁlippo’s syndrome (n  2),
I-cell disease (n  1), Krabbe’s disease (n  7), Tay-Sachs disease
(n 2), and adrenoleukodystrophy (n 5) with a mean age of 1.83
years were transplanted with an HLA 6/6 (n 3), 5/6 (n 14), 4/6
(n  14), or 3/6 (n  1) matched unit with a median of 8/6  107
nucleated cells/kg selected from COBLT banks (80%) or other
banks (20%). CBUs were screened for enzyme activity to prevent
use of a carrier donor. The cumulative incidence of neutrophil
engraftment and grade III/IV acute GvHD were 84% in a median
of 26 days and 19%, respectively. The probability of survival at 180
days and 2 years was 84%. Seven patients died, 1 before and 6 after
transplantation (1 of GvHD with infection, 3 of graft failure, 2 of
organ failure, and 1 of hemolytic anemia). The surviving patients
with MPS syndromes, Tay-Sachs disease, and Krabbe’s disease all
stabilized and/or gained skills posttransplantation. One of 5 pa-
tients with ALD experienced disease progression, whereas all oth-
ers stabilized and continue to gain developmental skills. Levels of
HLA disparity between recipient and donor determined by retro-
spective high-resolution DNA typing did not inﬂuence engraft-
ment, GvHD, or overall survival. The COBLT study represents
the ﬁrst prospective multicenter trial in children with inborn errors
of metabolism undergoing UCBT. UCBT provides rapid access to
donors and favorably alters the natural history of the disease and
should be considered for patients with metabolic diseases who are
eligible for transplantation therapy.
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BUSULFAN DOSE ESCALATION TO INCREASE GENE MARKING OF HE-
MATOPOIETIC STEM CELLS BY LENTIVIRAL VECTORS IN INFANT RHE-
SUS MONKEYS
Kohn, D.B.1, Kahl, C.A.1, Lee, C.I.2, Jiminez, D.F.2, Choi, C.1,
Pepper, K.A.1, Petersen, D.1, Fletcher, M.D.2, Leapley, A.C.2,
Burns, T.S.2, Ultsch, M.-N.2, Tarantal, A.F.2 1Childrens Hospital Los
Angeles, Los Angeles, CA; 2California National Primate Research Cen-
ter, Davis, CA.
Gene transfer to hematopoietic stem cells (HSCs) using lentiviral
vectors may be an attractive approach to treat a variety of diseases.
This can be accomplished in the context of an autologous bone
marrow transplantation (BMT), where HSC are transduced ex
vivo. The myeloablative drug busulfan can then be used to “make
space” in the bone marrow compartment, to allow efﬁcient reen-
graftment of the transduced cells. It is important to identify an
optimal busulfan dose that will result in efﬁcient long-term gene
marking and have the least toxicity. We performed a lentiviral
gene-marking study in infant rhesus macaques using escalating
doses of busulfan. Bone marrow (10–15 mL/kg) was harvested
from each monkey, followed by a single IV infusion of busulfan
over 2 hours in groups of 2–3 using busulfan at 0, 40, 80, 120, and
160 mg/m2 with dilantin seizure prophylaxis. Peripheral blood
busulfan levels were then followed over a period of 4 hours, and the
AUC was determined. CD34 cells were isolated from the har-
vested bone marrow, cultured for 24 hours in serum-free medium
with recombinant cytokines and transduced overnight with an
SIV-derived lentiviral vector pseudotyped with the VSV-G glyco-
protein. The vector contains a neomycin gene with a mutation in
the start codon that abolishes its expression and thus can serve as a
nonexpressed marker gene. The next morning, transduced cells
were washed and reinfused IV, approximately 48 hours after ad-
ministration of busulfan. Increasing dosages of busulfan resulted in
an increased AUC. However, variability in AUC at each dose level
( 1.5) was observed, suggesting relatively large interindividual
variations in busulfan clearance. At doses of 120 and 160 mg/m2
busulfan, neutrophil counts transiently dropped under 1000 cells/
L, and platelet counts dropped under 105/L, indicating dose-
related neutropenia and thrombocytopenia. Blood chemistries and
behavior appeared normal in all animals, and no seizures were
observed. Gene marking in mononuclear cells and granulocytes
will be measured at monthly intervals by determining the number
of integrated proviruses per cell with quantitative PCR. Together,
our results suggest that busulfan is safe and has no detectable
toxicity at these submyeloablative dosages in infant rhesus mon-
keys, except for the expected myelosuppressive effects.
We thank ESP Pharma for providing Busulfex for these studies.
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ENGRAFTMENT FOLLOWING REDUCED INTENSITY CONDITIONING
(RIC) WITH FLU-BU-ATG AND ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION (HSCT)—PEDIATRIC EXPERIENCE AT CHIL-
DREN’S MEMORIAL HOSPITAL
Duerst, R.E., Jacobsohn, D.A., Tse, W., Kletzel, M. Children’s Memo-
rial Hospital and Feinberg School of Medicine, Northwestern University,
Chicago, IL.
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